Changemakers on a mission (NL)

A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a trial coordinated by the University of Cambridge has found.

Not all cancer patients benefit from new drugs. To study which patients really do, doctors and researchers need access to the clinical data and tissue samples that patients provide in clinical studies. An international group of 53 breast cancer experts and patients representatives is therefore calling for better cooperation between academic institutions and the pharmaceutical sector. Their claim has been published in JAMA Oncology.

Pancreatic cancer is one of the most aggressive and challenging malignancies, with a prognosis that remains devastatingly poor. We sat down with Prof. Dr. Christelle Bouchart (ULB, Department of Radiation-Oncology at H.U.B. Institut Jules Bordet), the Investigator of the STEREOPAC-trial.

Two late-phase clinical trials in rare cancers will receive more than €11 million in funding following the second international ATTRACT call, co-funded by Anticancer Fund.